Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer & Metabolism
Published in: Cancer & Metabolism 1/2021

Open Access 01-12-2021 | Review

The diversity and breadth of cancer cell fatty acid metabolism

Authors: Shilpa R. Nagarajan, Lisa M. Butler, Andrew J. Hoy

Published in: Cancer & Metabolism | Issue 1/2021

Login to get access

Abstract

Tumor cellular metabolism exhibits distinguishing features that collectively enhance biomass synthesis while maintaining redox balance and cellular homeostasis. These attributes reflect the complex interactions between cell-intrinsic factors such as genomic-transcriptomic regulation and cell-extrinsic influences, including growth factor and nutrient availability. Alongside glucose and amino acid metabolism, fatty acid metabolism supports tumorigenesis and disease progression through a range of processes including membrane biosynthesis, energy storage and production, and generation of signaling intermediates. Here, we highlight the complexity of cellular fatty acid metabolism in cancer, the various inputs and outputs of the intracellular free fatty acid pool, and the numerous ways that these pathways influence disease behavior.
Literature
1.
2.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.PubMedPubMedCentralCrossRef
3.
Balaban S, Lee LS, Varney B, Aishah A, Gao Q, Shearer RF, et al. Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis. Mol Oncol. 2018;12(9):1623–38.PubMedPubMedCentralCrossRef
4.
Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, et al. Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. Mol Cancer Res. 2019;17(4):949–62.PubMedCrossRef
5.
Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, et al. Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 2017;5:1.PubMedPubMedCentralCrossRef
6.
7.
Ortmayr K, Dubuis S, Zampieri M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat Commun. 2019;10(1):1841.PubMedPubMedCentralCrossRef
8.
Chen PH, Cai L, Huffman K, Yang C, Kim J, Faubert B, et al. Metabolic diversity in human Non-small cell lung cancer cells. Mol Cell. 2019;76(5):838–51 e5.PubMedPubMedCentralCrossRef
9.
Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An integrated metabolic Atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29(1):104–16.PubMedPubMedCentralCrossRef
10.
Garg G, Yilmaz A, Kumar P, Turkoglu O, Mutch DG, Powell MA, et al. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study. Metabolomics. 2018;14(12):154.PubMedCrossRef
11.
Tan G, Wang H, Yuan J, Qin W, Dong X, Wu H, et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Sci Rep. 2017;7:46176.PubMedPubMedCentralCrossRef
12.
Lin HM, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, et al. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017;141(10):2112–20.PubMedCrossRef
13.
Bok R, Lee J, Sriram R, Keshari K, Sukumar S, Daneshmandi S, et al. The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized (13)C MRSI. Cancers (Basel). 2019;11(2):257.CrossRef
14.
Christen S, Lorendeau D, Schmieder R, Broekaert D, Metzger K, Veys K, et al. Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep. 2016;17(3):837–48.PubMedCrossRef
15.
Elia I, Doglioni G, Fendt SM. Metabolic hallmarks of metastasis formation. Trends Cell Biol. 2018;28(8):673–84.PubMedCrossRef
16.
Lebelo MT, Joubert AM, Visagie MH. Warburg effect and its role in tumourigenesis. Arch Pharm Res. 2019;42(10):833–47.PubMedCrossRef
17.
18.
Tanner JJ, Fendt SM, Becker DF. The proline cycle as a potential cancer therapy target. Biochemistry. 2018;57(25):3433–44.PubMedCrossRef
19.
Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 2019;572(7769):397–401.PubMedPubMedCentralCrossRef
20.
Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19(11):625–37.PubMedCrossRef
21.
22.
Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J. 2002;364(1):309–15.PubMedPubMedCentralCrossRef
23.
24.
25.
Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015;95:80–7.PubMedCrossRef
26.
Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol. 2018;19(5):281–96.PubMedCrossRef
27.
28.
29.
Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294(5548):1942–5.PubMedCrossRef
30.
Menon D, Salloum D, Bernfeld E, Gorodetsky E, Akselrod A, Frias MA, et al. Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid. J Biol Chem. 2017;292(15):6303–11.PubMedPubMedCentralCrossRef
31.
Nguyen TL, Nokin MJ, Egorov M, Tome M, Bodineau C, Di Primo C, et al. mTOR Inhibition via Displacement of Phosphatidic Acid Induces Enhanced Cytotoxicity Specifically in Cancer Cells. Cancer Res. 2018;78(18):5384–97.PubMedCrossRef
32.
Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, et al. Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression. Nat Commun. 2017;8:15747.PubMedPubMedCentralCrossRef
33.
34.
35.
36.
Jones RD, Liao J, Tong X, Xu D, Sun L, Li H, et al. Epoxy-oxylipins and soluble epoxide hydrolase metabolic pathway as targets for NSAID-induced gastroenteropathy and inflammation-associated carcinogenesis. Front Pharmacol. 2019;10:731.PubMedPubMedCentralCrossRef
37.
Schopfer FJ, Khoo NKH. Nitro-fatty acid logistics: formation, biodistribution, signaling, and pharmacology. Trends Endocrinol Metab. 2019;30(8):505–19.PubMedPubMedCentralCrossRef
38.
Mukherji M, Schofield CJ, Wierzbicki AS, Jansen GA, Wanders RJ, Lloyd MD. The chemical biology of branched-chain lipid metabolism. Prog Lipid Res. 2003;42(5):359–76.PubMedCrossRef
39.
40.
41.
42.
Jarc E, Kump A, Malavasic P, Eichmann TO, Zimmermann R, Petan T. Lipid droplets induced by secreted phospholipase A2 and unsaturated fatty acids protect breast cancer cells from nutrient and lipotoxic stress. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(3):247–65.PubMedCrossRef
43.
Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016;5:e10250.PubMedPubMedCentralCrossRef
44.
Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60.PubMedCrossRef
45.
Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013;110(22):8882–7.PubMedPubMedCentralCrossRef
46.
Glatz JF, Luiken JJ. From fat to FAT (CD36/SR-B2): Understanding the regulation of cellular fatty acid uptake. Biochimie. 2017;136:21–6.PubMedCrossRef
47.
Jay AG, Hamilton JA. The enigmatic membrane fatty acid transporter CD36: new insights into fatty acid binding and their effects on uptake of oxidized LDL. Prostaglandins Leukot Essent Fatty Acids. 2018;138:64–70.PubMedCrossRef
48.
Mann CJ, Khallou J, Chevreuil O, Troussard AA, Guermani LM, Launay K, et al. Mechanism of activation and functional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor. Biochemistry. 1995;34(33):10421–31.PubMedCrossRef
49.
Actis Dato V, Chiabrando GA. The role of low-density lipoprotein receptor-related protein 1 in lipid metabolism, glucose homeostasis and inflammation. Int J Mol Sci. 2018;19(6):1780.PubMedCentralCrossRef
50.
Shen WJ, Azhar S, Kraemer FB. SR-B1: A unique multifunctional receptor for cholesterol influx and efflux. Annu Rev Physiol. 2018;80:95–116.PubMedCrossRef
51.
52.
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019;11(478):eaau5758.PubMedCrossRef
53.
Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285–301.PubMedPubMedCentralCrossRef
54.
Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):41–5.PubMedCrossRef
55.
Yang P, Su C, Luo X, Zeng H, Zhao L, Wei L, et al. Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway. Cancer Lett. 2018;438:76–85.PubMedCrossRef
56.
Pan J, Fan Z, Wang Z, Dai Q, Xiang Z, Yuan F, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3beta/beta-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):52.PubMedPubMedCentralCrossRef
57.
Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, et al. Exogenous lipids promote the growth of breast cancer cells via CD36. Oncol Rep. 2017;38(4):2105–15.PubMedPubMedCentralCrossRef
58.
Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, et al. CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Rep. 2019;29(11):3405–20 e5.PubMedPubMedCentralCrossRef
59.
Nath A, Li I, Roberts LR, Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752.PubMedPubMedCentralCrossRef
60.
61.
Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, et al. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov. 2018;8(8):1006–25.PubMedPubMedCentralCrossRef
62.
Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med. 2014;52(12):1695–727.PubMedCrossRef
63.
Menard JA, Christianson HC, Kucharzewska P, Bourseau-Guilmain E, Svensson KJ, Lindqvist E, et al. Metastasis stimulation by hypoxia and acidosis-induced extracellular lipid uptake is mediated by proteoglycan-dependent endocytosis. Cancer Res. 2016;76(16):4828–40.PubMedCrossRef
64.
Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, et al. Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells. J Lipid Res. 2020;61(2):205–18.PubMedCrossRef
65.
Shen GM, Zhao YZ, Chen MT, Zhang FL, Liu XL, Wang Y, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J. 2012;441(2):675–83.PubMedCrossRef
66.
Sundelin JP, Stahlman M, Lundqvist A, Levin M, Parini P, Johansson ME, et al. Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. PLoS One. 2012;7(11):e48694.PubMedPubMedCentralCrossRef
67.
Reaves DK, Hoadley KA, Fagan-Solis KD, Jima DD, Bereman M, Thorpe L, et al. Nuclear localized LSR: a novel regulator of breast cancer behavior and tumorigenesis. Mol Cancer Res. 2017;15(2):165–78.PubMedCrossRef
68.
Bres EE, Faissner A. Low density receptor-related protein 1 interactions with the extracellular matrix: more than meets the eye. Front Cell Dev Biol. 2019;7:31.PubMedPubMedCentralCrossRef
69.
Michalopoulou E, Bulusu V, Kamphorst JJ. Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating. Br J Cancer. 2016;115(6):635–40.PubMedPubMedCentralCrossRef
70.
Recouvreux MV, Commisso C. Macropinocytosis: a metabolic adaptation to nutrient stress in cancer. Front Endocrinol (Lausanne). 2017;8:261.CrossRef
71.
Kim SM, Nguyen TT, Ravi A, Kubiniok P, Finicle BT, Jayashankar V, et al. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 2018;8(7):866–83.PubMedPubMedCentralCrossRef
72.
Kastaniotis AJ, Autio KJ, Keratar JM, Monteuuis G, Makela AM, Nair RR, et al. Mitochondrial fatty acid synthesis, fatty acids and mitochondrial physiology. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(1):39–48.PubMedCrossRef
73.
Nowinski SM, Solmonson A, Rusin SF, Maschek JA, Bensard CL, Fogarty S, et al. Mitochondrial fatty acid synthesis coordinates oxidative metabolism in mammalian mitochondria. Elife. 2020;9:e58041.PubMedPubMedCentralCrossRef
74.
75.
Liu X, Cooper DE, Cluntun AA, Warmoes MO, Zhao S, Reid MA, et al. Acetate production from glucose and coupling to mitochondrial metabolism in mammals. Cell. 2018;175(2):502–13 e13.PubMedPubMedCentralCrossRef
76.
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732–49.PubMedCrossRef
77.
Cerqueira NM, Oliveira EF, Gesto DS, Santos-Martins D, Moreira C, Moorthy HN, et al. Cholesterol Biosynthesis: A Mechanistic Overview. Biochemistry. 2016;55(39):5483–506.PubMedCrossRef
78.
Sivanand S, Viney I, Wellen KE. Spatiotemporal Control of Acetyl-CoA Metabolism in Chromatin Regulation. Trends Biochem Sci. 2018;43(1):61–74.PubMedCrossRef
79.
Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6(4):551–62.PubMedCrossRef
80.
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77.PubMedCrossRef
81.
Carrer A, Trefely S, Zhao S, Campbell SL, Norgard RJ, Schultz KC, et al. Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis. Cancer Discov. 2019;9(3):416–35.PubMedPubMedCentralCrossRef
82.
Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 2017;32(6):807–23 e12.PubMedCrossRef
83.
Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(2):631–40.PubMedCrossRef
84.
Cui Y, Xing P, Wang Y, Liu M, Qiu L, Ying G, et al. NADPH accumulation is responsible for apoptosis in breast cancer cells induced by fatty acid synthase inhibition. Oncotarget. 2017;8(20):32576–85.PubMedPubMedCentralCrossRef
85.
86.
Wei J, Leit S, Kuai J, Therrien E, Rafi S, Harwood HJ Jr, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019;568(7753):566–70.PubMedCrossRef
87.
Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, Steinhauser ML, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–9.PubMedPubMedCentralCrossRef
88.
Benjamin DI, Li DS, Lowe W, Heuer T, Kemble G, Nomura DK. Diacylglycerol metabolism and signaling is a driving force underlying FASN inhibitor sensitivity in cancer cells. ACS Chem Biol. 2015;10(7):1616–23.PubMedPubMedCentralCrossRef
89.
Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016;22(10):1108–19.PubMedPubMedCentralCrossRef
90.
Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV, Zaidi N. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One. 2014;9(9):e106913.PubMedPubMedCentralCrossRef
91.
Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, et al. TPD52 expression increases neutral lipid storage within cultured cells. J Cell Sci. 2015;128(17):3223–38.PubMedPubMedCentral
92.
RostamiRad A, Ebrahimi SSS, Sadeghi A, Taghikhani M, Meshkani R. Palmitate-induced impairment of autophagy turnover leads to increased apoptosis and inflammation in peripheral blood mononuclear cells. Immunobiology. 2018;223(3):269–78.PubMedCrossRef
93.
Kim DH, Cho YM, Lee KH, Jeong SW, Kwon OJ. Oleate protects macrophages from palmitate-induced apoptosis through the downregulation of CD36 expression. Biochem Biophys Res Commun. 2017;488(3):477–82.PubMedCrossRef
94.
Penke M, Schuster S, Gorski T, Gebhardt R, Kiess W, Garten A. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells. Lipids Health Dis. 2017;16(1):191.PubMedPubMedCentralCrossRef
95.
Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J Biol Chem. 2003;278(34):31861–70.PubMedCrossRef
96.
Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res. 2000;60(22):6353–8.PubMed
97.
Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res. 2009;11(2):R16.PubMedPubMedCentralCrossRef
98.
Baumann J, Wong J, Sun Y, Conklin DS. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer. 2016;16:551.PubMedPubMedCentralCrossRef
99.
Wu J, Wu Q, Li JJ, Chen C, Sun S, Wang CH, et al. Autophagy mediates free fatty acid effects on MDA-MB-231 cell proliferation, migration and invasion. Oncol Lett. 2017;14(4):4715–21.PubMedPubMedCentralCrossRef
100.
Boslem E, MacIntosh G, Preston AM, Bartley C, Busch AK, Fuller M, et al. A lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. Biochem J. 2011;435(1):267–76.PubMedCrossRef
101.
Luo F, Feng Y, Ma H, Liu C, Chen G, Wei X, et al. Neutral ceramidase activity inhibition is involved in palmitate-induced apoptosis in INS-1 cells. Endocr J. 2017;64(8):767–76.PubMedCrossRef
102.
Piccolis M, Bond LM, Kampmann M, Pulimeno P, Chitraju C, Jayson CBK, et al. Probing the global cellular responses to lipotoxicity caused by saturated fatty acids. Mol Cell. 2019;74(1):32–44 e8.PubMedPubMedCentralCrossRef
103.
Aloulou A, Rahier R, Arhab Y, Noiriel A, Abousalham A. Phospholipases: an overview. Methods Mol Biol. 1835;2018:69–105.
104.
105.
Wepy JA, Galligan JJ, Kingsley PJ, Xu S, Goodman MC, Tallman KA, et al. Lysophospholipases cooperate to mediate lipid homeostasis and lysophospholipid signaling. J Lipid Res. 2019;60(2):360–74.PubMedCrossRef
106.
Adibekian A, Martin BR, Chang JW, Hsu KL, Tsuboi K, Bachovchin DA, et al. Characterization of a selective, reversible inhibitor of lysophospholipase 2 (LYPLA2). Bethesda: Probe Reports from the NIH Molecular Libraries Program; 2010.
107.
Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, et al. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A(2)alpha via AKT in prostate cancer cells. Oncotarget. 2014;5(15):6289–99.PubMedPubMedCentralCrossRef
108.
Naini SM, Choukroun GJ, Ryan JR, Hentschel DM, Shah JV, Bonventre JV. Cytosolic phospholipase A2alpha regulates G1 progression through modulating FOXO1 activity. FASEB J. 2016;30(3):1155–70.PubMedCrossRef
109.
Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM. HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One. 2013;8(4):e62610.PubMedPubMedCentralCrossRef
110.
Mohammed A, Zhang C, Zhang S, Shen Q, Li J, Tang Z, et al. Inhibition of cell proliferation and migration in nonsmall cell lung cancer cells through the suppression of LYPLA1. Oncol Rep. 2019;41(2):973–80.PubMed
111.
Duncan JA, Gilman AG. A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS). J Biol Chem. 1998;273(25):15830–7.PubMedCrossRef
112.
Coant N, Sakamoto W, Mao C, Hannun YA. Ceramidases, roles in sphingolipid metabolism and in health and disease. Adv Biol Regul. 2017;63:122–31.PubMedCrossRef
113.
Govindarajah N, Clifford R, Bowden D, Sutton PA, Parsons JL, Vimalachandran D. Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy. Crit Rev Oncol Hematol. 2019;138:104–11.PubMedCrossRef
114.
115.
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.PubMedCrossRef
116.
117.
Senkal CE, Salama MF, Snider AJ, Allopenna JJ, Rana NA, Koller A, et al. Ceramide is metabolized to acylceramide and stored in lipid droplets. Cell Metab. 2017;25(3):686–97.PubMedPubMedCentralCrossRef
118.
Zechner R, Madeo F, Kratky D. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nat Rev Mol Cell Biol. 2017;18(11):671–84.PubMedCrossRef
119.
120.
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19(3):393–406.PubMedPubMedCentralCrossRef
121.
Przybytkowski E, Joly E, Nolan CJ, Hardy S, Francoeur AM, Langelier Y, et al. Upregulation of cellular triacylglycerol - free fatty acid cycling by oleate is associated with long-term serum-free survival of human breast cancer cells. Biochem Cell Biol. 2007;85(3):301–10.PubMedCrossRef
122.
Ackerman D, Tumanov S, Qiu B, Michalopoulou E, Spata M, Azzam A, et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 2018;24(10):2596–605 e5.PubMedPubMedCentralCrossRef
123.
Cruz ALS, Barreto EA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: platforms with multiple functions in cancer hallmarks. Cell Death Dis. 2020;11(2):105.PubMedPubMedCentralCrossRef
124.
125.
Li Y, Zalzala M, Jadhav K, Xu Y, Kasumov T, Yin L, et al. Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology. 2016;63(6):1860–74.PubMedCrossRef
126.
Turpin SM, Hoy AJ, Brown RD, Rudaz CG, Honeyman J, Matzaris M, et al. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia. 2011;54(1):146–56.PubMedCrossRef
127.
128.
129.
Tomin T, Fritz K, Gindlhuber J, Waldherr L, Pucher B, Thallinger GG, et al. Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more-aggressive phenotype in A549 lung carcinoma cells. J Proteome Res. 2018;17(4):1415–25.PubMedCrossRef
130.
Zhang X, Saarinen AM, Hitosugi T, Wang Z, Wang L, Ho TH, et al. Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. Elife. 2017;6:e31132.PubMedPubMedCentralCrossRef
131.
Xie H, Heier C, Kien B, Vesely PW, Tang Z, Sexl V, et al. Adipose triglyceride lipase activity regulates cancer cell proliferation via AMP-kinase and mTOR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020(9):158737.
132.
VandeKopple MJ, Wu J, Auer EN, Giaccia AJ, Denko NC, Papandreou I. HILPDA regulates lipid metabolism, lipid droplet abundance, and response to microenvironmental stress in solid tumors. Mol Cancer Res. 2019;17(10):2089–101.PubMedPubMedCentralCrossRef
133.
Wang YY, Attane C, Milhas D, Dirat B, Dauvillier S, Guerard A, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight. 2017;2(4):e87489.PubMedPubMedCentralCrossRef
134.
Zhang X, Heckmann BL, Campbell LE, Liu J. G0S2: A small giant controller of lipolysis and adipose-liver fatty acid flux. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(10 Pt B):1146–54.PubMedCrossRef
135.
Mitra R, Le TT, Gorjala P, Goodman OB Jr. Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5. BMC Cancer. 2017;17(1):631.PubMedPubMedCentralCrossRef
136.
Chen G, Zhou G, Aras S, He Z, Lucas S, Podgorski I, et al. Loss of ABHD5 promotes the aggressiveness of prostate cancer cells. Sci Rep. 2017;7(1):13021.PubMedPubMedCentralCrossRef
137.
Zierler KA, Zechner R, Haemmerle G. Comparative gene identification-58/alpha/beta hydrolase domain 5: more than just an adipose triglyceride lipase activator? Curr Opin Lipidol. 2014;25(2):102–9.PubMedPubMedCentralCrossRef
138.
Kraemer FB, Shen WJ. Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. J Lipid Res. 2002;43(10):1585–94.PubMedCrossRef
139.
Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011;18(7):846–56.PubMedPubMedCentralCrossRef
140.
Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140(1):49–61.PubMedPubMedCentralCrossRef
141.
Tang Z, Xie H, Heier C, Huang J, Zheng Q, Eichmann TO, et al. Enhanced monoacylglycerol lipolysis by ABHD6 promotes NSCLC pathogenesis. EBioMedicine. 2020;53:102696.PubMedPubMedCentralCrossRef
142.
Lian J, Nelson R, Lehner R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell. 2018;9(2):178–95.PubMedCrossRef
143.
Haemmerle G, Lass A. Genetically modified mouse models to study hepatic neutral lipid mobilization. Biochim Biophys Acta Mol Basis Dis. 2019;1865(5):879–94.PubMedCrossRef
144.
Ghosh S. Early steps in reverse cholesterol transport: cholesteryl ester hydrolase and other hydrolases. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):136–41.PubMedCrossRef
145.
146.
Bai Y, Meng L, Han L, Jia Y, Zhao Y, Gao H, et al. Lipid storage and lipophagy regulates ferroptosis. Biochem Biophys Res Commun. 2019;508(4):997–1003.PubMedCrossRef
147.
Schroeder B, Schulze RJ, Weller SG, Sletten AC, Casey CA, McNiven MA. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology. 2015;61(6):1896–907.PubMedCrossRef
148.
Dupont N, Chauhan S, Arko-Mensah J, Castillo EF, Masedunskas A, Weigert R, et al. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. Curr Biol. 2014;24(6):609–20.PubMedPubMedCentralCrossRef
149.
Mukhopadhyay S, Schlaepfer IR, Bergman BC, Panda PK, Praharaj PP, Naik PP, et al. ATG14 facilitated lipophagy in cancer cells induce ER stress mediated mitoptosis through a ROS dependent pathway. Free Radic Biol Med. 2017;104:199–213.PubMedCrossRef
150.
Xu G, Jiang Y, Xiao Y, Liu XD, Yue F, Li W, et al. Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget. 2016;7(5):6255–65.PubMedCrossRef
151.
Panda PK, Patra S, Naik PP, Praharaj PP, Mukhopadhyay S, Meher BR, et al. Deacetylation of LAMP1 drives lipophagy-dependent generation of free fatty acids by Abrus agglutinin to promote senescence in prostate cancer. J Cell Physiol. 2020;235(3):2776–91.PubMedCrossRef
152.
McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019;62:109336.PubMedCrossRef
153.
154.
Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta. 2012;1821(5):852–7.PubMedCrossRef
155.
Tang Y, Zhou J, Hooi SC, Jiang YM, Lu GD. Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases. Oncol Lett. 2018;16(2):1390–6.PubMedPubMedCentral
156.
Radif Y, Ndiaye H, Kalantzi V, Jacobs R, Hall A, Minogue S, et al. The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells. Mol Cell Biochem. 2018;448(1-2):275–86.PubMedPubMedCentralCrossRef
157.
Liu KT, Yeh IJ, Chou SK, Yen MC, Kuo PL. Regulatory mechanism of fatty acidCoA metabolic enzymes under endoplasmic reticulum stress in lung cancer. Oncol Rep. 2018;40(5):2674–82.PubMed
158.
Wright HJ, Hou J, Xu B, Cortez M, Potma EO, Tromberg BJ, et al. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci U S A. 2017;114(32):E6556–E65.PubMedPubMedCentralCrossRef
159.
Tillander V, Alexson SEH, Cohen DE. Deactivating Fatty Acids: Acyl-CoA thioesterase-mediated control of lipid metabolism. Trends Endocrinol Metab. 2017;28(7):473–84.PubMedPubMedCentralCrossRef
160.
Kirkby B, Roman N, Kobe B, Kellie S, Forwood JK. Functional and structural properties of mammalian acyl-coenzyme A thioesterases. Prog Lipid Res. 2010;49(4):366–77.PubMedCrossRef
161.
Jung SH, Lee HC, Hwang HJ, Park HA, Moon YA, Kim BC, et al. Acyl-CoA thioesterase 7 is involved in cell cycle progression via regulation of PKCzeta-p53-p21 signaling pathway. Cell Death Dis. 2017;8(5):e2793.PubMedPubMedCentralCrossRef
162.
Forwood JK, Thakur AS, Guncar G, Marfori M, Mouradov D, Meng W, et al. Structural basis for recruitment of tandem hotdog domains in acyl-CoA thioesterase 7 and its role in inflammation. Proc Natl Acad Sci U S A. 2007;104(25):10382–7.PubMedPubMedCentralCrossRef
163.
Wang F, Wu J, Qiu Z, Ge X, Liu X, Zhang C, et al. ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma. Hum Pathol. 2018;77:35–44.PubMedCrossRef
164.
Hung JY, Chiang SR, Liu KT, Tsai MJ, Huang MS, Shieh JM, et al. Overexpression and proliferation dependence of acyl-CoA thioesterase 11 and 13 in lung adenocarcinoma. Oncol Lett. 2017;14(3):3647–56.PubMedPubMedCentralCrossRef
165.
Bakshi I, Brown SHJ, Brandon AE, Suryana E, Mitchell TW, Turner N, et al. Increasing acyl CoA thioesterase activity alters phospholipid profile without effect on insulin action in skeletal muscle of rats. Sci Rep. 2018;8(1):13967.PubMedPubMedCentralCrossRef
166.
Wall VZ, Barnhart S, Kramer F, Kanter JE, Vivekanandan-Giri A, Pennathur S, et al. Inflammatory stimuli induce acyl-CoA thioesterase 7 and remodeling of phospholipids containing unsaturated long (>/=C20)-acyl chains in macrophages. J Lipid Res. 2017;58(6):1174–85.PubMedPubMedCentralCrossRef
167.
Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab. 2009;297(1):E28–37.PubMedCrossRef
168.
Behrouzian B, Buist PH. Mechanism of fatty acid desaturation: a bioorganic perspective. Prostaglandins Leukot Essent Fatty Acids. 2003;68(2):107–12.PubMedCrossRef
169.
Enoch HG, Catala A, Strittmatter P. Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J Biol Chem. 1976;251(16):5095–103.PubMedCrossRef
170.
Zhang JY, Qin X, Liang A, Kim E, Lawrence P, Park WJ, et al. Fads3 modulates docosahexaenoic acid in liver and brain. Prostaglandins Leukot Essent Fatty Acids. 2017;123:25–32.PubMedPubMedCentralCrossRef
171.
Karsai G, Lone M, Kutalik Z, Brenna JT, Li H, Pan D, et al. FADS3 is a Delta14Z sphingoid base desaturase that contributes to gender differences in the human plasma sphingolipidome. J Biol Chem. 2020;295(7):1889–97.PubMedCrossRef
172.
Rioux V, Pedrono F, Blanchard H, Duby C, Boulier-Monthean N, Bernard L, et al. Trans-vaccenate is Delta13-desaturated by FADS3 in rodents. J Lipid Res. 2013;54(12):3438–52.PubMedPubMedCentralCrossRef
173.
Igal RA. Stearoyl CoA desaturase-1: New insights into a central regulator of cancer metabolism. Biochim Biophys Acta. 2016;1861(12 Pt A):1865–80.PubMedCrossRef
174.
Peck B, Schulze A. Lipid desaturation - the next step in targeting lipogenesis in cancer? FEBS J. 2016;283(15):2767–78.PubMedCrossRef
175.
Ran H, Zhu Y, Deng R, Zhang Q, Liu X, Feng M, et al. Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN. J Exp Clin Cancer Res. 2018;37(1):54.PubMedPubMedCentralCrossRef
176.
Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79(20):5355–66.PubMedPubMedCentralCrossRef
177.
Li W, Bai H, Liu S, Cao D, Wu H, Shen K, et al. Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression. Oncotarget. 2018;9(15):12064–78.PubMedPubMedCentralCrossRef
178.
Piao C, Cui X, Zhan B, Li J, Li Z, Li Z, et al. Inhibition of stearoyl CoA desaturase-1 activity suppresses tumour progression and improves prognosis in human bladder cancer. J Cell Mol Med. 2019;23(3):2064–76.PubMedCrossRef
179.
Wang J, Xu Y, Zhu L, Zou Y, Kong W, Dong B, et al. High expression of stearoyl-CoA desaturase 1 predicts poor prognosis in patients with clear-cell renal cell carcinoma. PLoS One. 2016;11(11):e0166231.PubMedPubMedCentralCrossRef
180.
Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566(7744):403–6.PubMedPubMedCentralCrossRef
181.
Ducheix S, Peres C, Hardfeldt J, Frau C, Mocciaro G, Piccinin E, et al. Deletion of stearoyl-CoA desaturase-1 from the intestinal epithelium promotes inflammation and tumorigenesis, reversed by dietary oleate. Gastroenterology. 2018;155(5):1524–38 e9.PubMedCrossRef
182.
Angelucci C, D'Alessio A, Iacopino F, Proietti G, Di Leone A, Masetti R, et al. Pivotal role of human stearoyl-CoA desaturases (SCD1 and 5) in breast cancer progression: oleic acid-based effect of SCD1 on cell migration and a novel pro-cell survival role for SCD5. Oncotarget. 2018;9(36):24364–80.PubMedPubMedCentralCrossRef
183.
Chen L, Ren J, Yang L, Li Y, Fu J, Li Y, et al. Stearoyl-CoA desaturase-1 mediated cell apoptosis in colorectal cancer by promoting ceramide synthesis. Sci Rep. 2016;6:19665.PubMedPubMedCentralCrossRef
184.
Koeberle A, Loser K, Thurmer M. Stearoyl-CoA desaturase-1 and adaptive stress signaling. Biochim Biophys Acta. 2016;1861(11):1719–26.PubMedCrossRef
185.
Tocher DR, Leaver MJ, Hodgson PA. Recent advances in the biochemistry and molecular biology of fatty acyl desaturases. Prog Lipid Res. 1998;37(2-3):73–117.PubMedCrossRef
186.
Lane J, Mansel RE, Jiang WG. Expression of human delta-6-desaturase is associated with aggressiveness of human breast cancer. Int J Mol Med. 2003;12(2):253–7.PubMed
187.
Kang YP, Yoon JH, Long NP, Koo GB, Noh HJ, Oh SJ, et al. Spheroid-induced epithelial-mesenchymal transition provokes global alterations of breast cancer lipidome: a multi-layered omics analysis. Front Oncol. 2019;9:145.PubMedPubMedCentralCrossRef
188.
Wang D, Lin Y, Gao B, Yan S, Wu H, Li Y, et al. Reduced expression of FADS1 predicts worse prognosis in non-small-cell lung cancer. J Cancer. 2016;7(10):1226–32.PubMedPubMedCentralCrossRef
189.
Du Y, Yan SM, Gu WY, He F, Huang LY, Li M, et al. Decreased expression of FADS1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2015;16(12):5089–94.PubMedCrossRef
190.
Park HG, Park WJ, Kothapalli KS, Brenna JT. The fatty acid desaturase 2 (FADS2) gene product catalyzes Delta4 desaturation to yield n-3 docosahexaenoic acid and n-6 docosapentaenoic acid in human cells. FASEB J. 2015;29(9):3911–9.PubMedPubMedCentralCrossRef
191.
Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019;26(3):420–32 e9.PubMedPubMedCentralCrossRef
192.
Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8.PubMedCrossRef
193.
Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature. 2020;585(7826):603–8.PubMedCrossRefPubMedCentral
194.
Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90.PubMedCrossRef
195.
Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–14.PubMedCrossRef
196.
Kihara A. Very long-chain fatty acids: elongation, physiology and related disorders. J Biochem. 2012;152(5):387–95.PubMedCrossRef
197.
198.
Naganuma T, Sato Y, Sassa T, Ohno Y, Kihara A. Biochemical characterization of the very long-chain fatty acid elongase ELOVL7. FEBS letters. 2011;585(20):3337–41.PubMedCrossRef
199.
Yamashita Y, Nishiumi S, Kono S, Takao S, Azuma T, Yoshida M. Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer. BMC Cancer. 2017;17(1):589.PubMedPubMedCentralCrossRef
200.
Marien E, Meister M, Muley T, Fieuws S, Bordel S, Derua R, et al. Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. Int J Cancer. 2015;137(7):1539–48.PubMedPubMedCentralCrossRef
201.
Su YC, Feng YH, Wu HT, Huang YS, Tung CL, Wu P, et al. Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression. Sci Rep. 2018;8(1):6586.PubMedPubMedCentralCrossRef
202.
Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, et al. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget. 2016;7(11):12582–97.PubMedPubMedCentralCrossRef
203.
Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Research. 2009;69:8133–40.PubMedCrossRef
204.
Mika A, Kobiela J, Czumaj A, Chmielewski M, Stepnowski P, Sledzinski T. Hyper-elongation in colorectal cancer tissue—cerotic acid is a potential novel serum metabolic marker of colorectal malignancies. Cell Physiol Biochem. 2017;41(2):722–30.PubMedCrossRef
205.
Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, et al. Glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer discovery. 2019;9(9):1248–67.PubMedPubMedCentralCrossRef
206.
Naguib A, Bencze G, Engle DD, Chio II, Herzka T, Watrud K, et al. p53 mutations change phosphatidylinositol acyl chain composition. Cell Rep. 2015;10(1):8–19.PubMedCrossRef
207.
Panagiotopoulos AA, Kalyvianaki K, Castanas E, Kampa M. Eicosanoids in prostate cancer. Cancer Metastasis Rev. 2018;37(2-3):237–43.PubMedCrossRef
208.
Kim W, Deik A, Gonzalez C, Gonzalez ME, Fu F, Ferrari M, et al. Polyunsaturated fatty acid desaturation is a mechanism for glycolytic NAD(+) recycling. Cell Metab. 2019;29(4):856–70 e7.PubMedPubMedCentralCrossRef
209.
Robert J, Montaudon D, Hugues P. Incorporation and metabolism of exogenous fatty acids by cultured normal and tumoral glial cells. Biochim Biophys Acta. 1983;752(3):383–95.PubMedCrossRef
210.
Lee WN, Lim S, Bassilian S, Bergner EA, Edmond J. Fatty acid cycling in human hepatoma cells and the effects of troglitazone. J Biol Chem. 1998;273(33):20929–34.PubMedCrossRef
211.
Islinger M, Costello JL, Kors S, Soupene E, Levine TP, Kuypers FA, et al. The diversity of ACBD proteins—from lipid binding to protein modulators and organelle tethers. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118675.PubMedPubMedCentralCrossRef
212.
Neess D, Bek S, Engelsby H, Gallego SF, Faergeman NJ. Long-chain acyl-CoA esters in metabolism and signaling: role of acyl-CoA binding proteins. Prog Lipid Res. 2015;59:1–25.PubMedCrossRef
213.
Duman C, Yaqubi K, Hoffmann A, Acikgoz AA, Korshunov A, Bendszus M, et al. Acyl-CoA-binding protein drives glioblastoma tumorigenesis by sustaining fatty acid oxidation. Cell Metab. 2019;30(2):274–89 e5.PubMedCrossRef
214.
Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, et al. Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res. 2009;50(Suppl):S9–14.PubMedPubMedCentralCrossRef
215.
216.
Casares D, Escriba PV, Rossello CA. Membrane lipid composition: effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Mol Sci. 2019;20(9):2167.PubMedCentralCrossRef
217.
Saito K, Arai E, Maekawa K, Ishikawa M, Fujimoto H, Taguchi R, et al. Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Sci Rep. 2016;6:28932.PubMedPubMedCentralCrossRef
218.
Butler L, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245–93.PubMedCrossRefPubMedCentral
219.
Karasawa K, Tanigawa K, Harada A, Yamashita A. Transcriptional regulation of Acyl-CoA:glycerol-sn-3-phosphate acyltransferases. Int J Mol Sci. 2019;20(4):964.PubMedCentralCrossRef
220.
Watt MJ, Holmes AG, Steinberg GR, Mesa JL, Kemp BE, Febbraio MA. Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004;287(1):E120–7.PubMedCrossRef
221.
Bradley RM, Duncan RE. The lysophosphatidic acid acyltransferases (acylglycerophosphate acyltransferases) family: one reaction, five enzymes, many roles. Curr Opin Lipidol. 2018;29(2):110–5.PubMedCrossRef
222.
Zhang P, Reue K. Lipin proteins and glycerolipid metabolism: roles at the ER membrane and beyond. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1583–95.PubMedCrossRef
223.
Merida I, Arranz-Nicolas J, Rodriguez-Rodriguez C, Avila-Flores A. Diacylglycerol kinase control of protein kinase C. Biochem J. 2019;476(8):1205–19.PubMedCrossRef
224.
Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev Cell. 2013;24(4):384–99.PubMedPubMedCentralCrossRef
225.
Gao M, Huang X, Song BL, Yang H. The biogenesis of lipid droplets: lipids take center stage. Prog Lipid Res. 2019;75:100989.PubMedCrossRef
226.
227.
Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. Prog Lipid Res. 2015;58:51–75.PubMedCrossRef
228.
Zhang D, Shi R, Xiang W, Kang X, Tang B, Li C, et al. The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages. Signal Transduct Target Ther. 2020;5:24.PubMedPubMedCentralCrossRef
229.
Pellon-Maison M, Montanaro MA, Lacunza E, Garcia-Fabiani MB, Soler-Gerino MC, Cattaneo ER, et al. Glycerol-3-phosphate acyltranferase-2 behaves as a cancer testis gene and promotes growth and tumorigenicity of the breast cancer MDA-MB-231 cell line. PLoS One. 2014;9(6):e100896.PubMedPubMedCentralCrossRef
230.
Marchan R, Buttner B, Lambert J, Edlund K, Glaeser I, Blaszkewicz M, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma. Cancer Res. 2017;77(17):4589–601.PubMedCrossRef
231.
McDermott MI, Wang Y, Wakelam MJO, Bankaitis VA. Mammalian phospholipase D: function, and therapeutics. Prog Lipid Res. 2020;78:101018.PubMedCrossRef
232.
Yang L, Ma HL. MiRNA-584 suppresses the progression of ovarian cancer by negatively regulating LPIN1. Eur Rev Med Pharmacol Sci. 2020;24(3):1062–71.PubMed
233.
Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang Q, et al. Exosomal miR-451a Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting LPIN1. Cell Physiol Biochem. 2019;53(1):19–35.PubMedCrossRef
234.
He J, Zhang F, Tay LWR, Boroda S, Nian W, Levental KR, et al. Lipin-1 regulation of phospholipid synthesis maintains endoplasmic reticulum homeostasis and is critical for triple-negative breast cancer cell survival. FASEB J. 2017;31(7):2893–904.PubMedPubMedCentralCrossRef
235.
Dinarvand N, Khanahmad H, Hakimian SM, Sheikhi A, Rashidi B, Bakhtiari H, et al. Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene. J Cell Physiol. 2020;235(7-8):5835–46.PubMedCrossRef
236.
Yamaki A, Akiyama R, Murakami C, Takao S, Murakami Y, Mizuno S, et al. Diacylglycerol kinase alpha-selective inhibitors induce apoptosis and reduce viability of melanoma and several other cancer cell lines. J Cell Biochem. 2019;120(6):10043–56.PubMedCrossRef
237.
Chen J, Zhang W, Wang Y, Zhao D, Wu M, Fan J, et al. The diacylglycerol kinase alpha (DGKalpha)/Akt/NF-kappaB feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner. Oncogene. 2019;38(14):2533–50.PubMedCrossRef
238.
Liu K, Kunii N, Sakuma M, Yamaki A, Mizuno S, Sato M, et al. A novel diacylglycerol kinase alpha-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response. J Lipid Res. 2016;57(3):368–79.PubMedPubMedCentralCrossRef
239.
Diao J, Wu C, Zhang J, Liu J, Zhang X, Hao P, et al. Loss of Diacylglycerol Kinase-Zeta Inhibits Cell Proliferation and Survival in Human Gliomas. Mol Neurobiol. 2016;53(8):5425–35.PubMedCrossRef
240.
Gu X, Wan G, Chen N, Li J, Chen B, Tang Y, et al. DGKzeta plays crucial roles in the proliferation and tumorigenicity of human glioblastoma. Int J Biol Sci. 2019;15(9):1872–81.PubMedPubMedCentralCrossRef
241.
Guo Z, Jia J, Yao M, Kang J, Wang Y, Yan X, et al. Diacylglycerol kinase gamma predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. Exp Cell Res. 2018;373(1-2):211–20.PubMedCrossRef
242.
Kai M, Yamamoto E, Sato A, Yamano HO, Niinuma T, Kitajima H, et al. Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer. Mol Carcinog. 2017;56(7):1743–52.PubMedCrossRef
243.
244.
Bhatt-Wessel B, Jordan TW, Miller JH, Peng L. Role of DGAT enzymes in triacylglycerol metabolism. Arch Biochem Biophys. 2018;655:1–11.PubMedCrossRef
245.
Hernandez-Corbacho MJ, Obeid LM. A novel role for DGATs in cancer. Adv Biol Regul. 2019;72:89–101.PubMedCrossRef
246.
Cheng X, Geng F, Pan M, Wu X, Zhong Y, Wang C, et al. Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress. Cell Metab. 2020;32(2):229–42 e8.PubMedCrossRefPubMedCentral
247.
Nardi F, Franco OE, Fitchev P, Morales A, Vickman RE, Hayward SW, et al. DGAT1 inhibitor suppresses prostate tumor growth and migration by regulating intracellular lipids and non-centrosomal MTOC protein GM130. Sci Rep. 2019;9(1):3035.PubMedPubMedCentralCrossRef
248.
Li Y, Li T, Jin Y, Shen J. Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression. Biomed Pharmacother. 2019;115:108950.PubMedCrossRef
249.
Chitraju C, Walther TC, Farese RV Jr. The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes. J Lipid Res. 2019;60(6):1112–20.PubMedPubMedCentralCrossRef
250.
Lowther J, Naismith JH, Dunn TM, Campopiano DJ. Structural, mechanistic and regulatory studies of serine palmitoyltransferase. Biochem Soc Trans. 2012;40(3):547–54.PubMedCrossRef
251.
Ventura AE, Mestre B, Silva LC. Ceramide domains in health and disease: a biophysical perspective. Adv Exp Med Biol. 2019;1159:79–108.PubMedCrossRef
252.
D'Angelo G, Moorthi S, Luberto C. Role and function of sphingomyelin biosynthesis in the development of cancer. Adv Cancer Res. 2018;140:61–96.PubMedCrossRef
253.
Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;35(50):6378–88.PubMedPubMedCentralCrossRef
254.
Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, et al. Inhibition of SOAT1 suppresses glioblastoma growth via Blocking SREBP-1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48.PubMedPubMedCentralCrossRef
255.
Navarro-Imaz H, Chico Y, Rueda Y, Fresnedo O. Channeling of newly synthesized fatty acids to cholesterol esterification limits triglyceride synthesis in SND1-overexpressing hepatoma cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(2):137–46.PubMedCrossRef
256.
Lands WE. Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis. J Biol Chem. 1958;231(2):883–8.PubMedCrossRef
257.
Kita Y, Shindou H, Shimizu T. Cytosolic phospholipase A2 and lysophospholipid acyltransferases. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(6):838–45.PubMedCrossRef
258.
Abdelzaher E, Mostafa MF. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. Tumour Biol. 2015;36(7):5473–83.PubMedCrossRef
259.
Lebok P, von Hassel A, Meiners J, Hube-Magg C, Simon R, Hoflmayer D, et al. Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging (Albany NY). 2019;11(18):7796–804.PubMedPubMedCentralCrossRef
260.
Uehara T, Kikuchi H, Miyazaki S, Iino I, Setoguchi T, Hiramatsu Y, et al. Overexpression of lysophosphatidylcholine acyltransferase 1 and concomitant lipid alterations in gastric cancer. Ann Surg Oncol. 2016;23(Suppl 2):S206–13.PubMedCrossRef
261.
Mansilla F, da Costa KA, Wang S, Kruhoffer M, Lewin TM, Orntoft TF, et al. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. J Mol Med (Berl). 2009;87(1):85–97.PubMedCrossRef
262.
Zhou X, Lawrence TJ, He Z, Pound CR, Mao J, Bigler SA. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Exp Mol Pathol. 2012;92(1):105–10.PubMedCrossRef
263.
Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol. 2013;7(6):1001–11.PubMedPubMedCentralCrossRef
264.
Du Y, Wang Q, Zhang X, Wang X, Qin C, Sheng Z, et al. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):66.PubMedPubMedCentralCrossRef
265.
Morita Y, Sakaguchi T, Ikegami K, Goto-Inoue N, Hayasaka T, Hang VT, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol. 2013;59(2):292–9.PubMedCrossRef
266.
Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab. 2019;30(3):525–38 e8.PubMedPubMedCentralCrossRef
267.
268.
Cotte AK, Aires V, Fredon M, Limagne E, Derangere V, Thibaudin M, et al. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun. 2018;9(1):322.PubMedPubMedCentralCrossRef
269.
Agarwal AK, Garg A. Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 11: upregulated in breast and cervical cancers. J Lipid Res. 2010;51(8):2143–52.PubMedPubMedCentralCrossRef
270.
Wang B, Rong X, Palladino END, Wang J, Fogelman AM, Martin MG, et al. Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis. Cell Stem Cell. 2018;22(2):206–20 e4.PubMedPubMedCentralCrossRef
271.
Saliakoura M, Reynoso-Moreno I, Pozzato C, Rossi Sebastiano M, Galie M, Gertsch J, et al. The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer. Oncogene. 2020;39(14):2948–60.PubMedPubMedCentralCrossRef
272.
Chen B, Sun Y, Niu J, Jarugumilli GK, Wu X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Cell Chem Biol. 2018;25(7):817–31.PubMedPubMedCentralCrossRef
273.
Lanyon-Hogg T, Faronato M, Serwa RA, Tate EW. Dynamic protein acylation: new substrates, mechanisms, and drug targets. Trends Biochem Sci. 2017;42(7):566–81.PubMedCrossRef
274.
275.
276.
Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92–100.PubMedPubMedCentralCrossRef
277.
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22(4):427–32.PubMedPubMedCentralCrossRef
278.
279.
Qu Q, Zeng F, Liu X, Wang QJ, Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis. 2016;7:e2226.PubMedPubMedCentralCrossRef
280.
Aiderus A, Black MA, Dunbier AK. Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. BMC Cancer. 2018;18(1):805.PubMedPubMedCentralCrossRef
281.
Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8(1):1769.PubMedPubMedCentralCrossRef
282.
Huang J, Duran A, Reina-Campos M, Valencia T, Castilla EA, Muller TD, et al. Adipocyte p62/SQSTM1 suppresses tumorigenesis through opposite regulations of metabolism in adipose tissue and tumor. Cancer Cell. 2018;33(4):770–84 e6.PubMedPubMedCentralCrossRef
283.
Hoehn KL, Turner N, Swarbrick MM, Wilks D, Preston E, Phua Y, et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab. 2010;11(1):70–6.PubMedPubMedCentralCrossRef
284.
Corbet C, Pinto A, Martherus R, Santiago de Jesus JP, Polet F, Feron O. Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation. Cell Metab. 2016;24(2):311–23.PubMedCrossRef
285.
Yang JH, Kim NH, Yun JS, Cho ES, Cha YH, Cho SB, et al. Snail augments fatty acid oxidation by suppression of mitochondrial ACC2 during cancer progression. Life Sci Alliance. 2020;3(7):e202000683.PubMedPubMedCentralCrossRef
286.
Cheng S, Wang G, Wang Y, Cai L, Qian K, Ju L, et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARgamma-mediated pathway in bladder cancer. Clin Sci (Lond). 2019;133(15):1745–58.PubMedCrossRef
287.
Park JH, Vithayathil S, Kumar S, Sung PL, Dobrolecki LE, Putluri V, et al. Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 2016;14(9):2154–65.PubMedPubMedCentralCrossRef
288.
Joshi M, Stoykova GE, Salzmann-Sullivan M, Dzieciatkowska M, Liebman LN, Deep G, et al. CPT1A supports castration-resistant prostate cancer in androgen-deprived conditions. Cells. 2019;8(10):1115.PubMedCentralCrossRef
289.
Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, et al. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics. 2018;8(9):2329–47.PubMedPubMedCentralCrossRef
290.
Yao CH, Liu GY, Wang R, Moon SH, Gross RW, Patti GJ. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of beta-oxidation. PLoS Biol. 2018;16(3):e2003782.PubMedPubMedCentralCrossRef
291.
Iglesias-Gato D, Wikstrom P, Tyanova S, Lavallee C, Thysell E, Carlsson J, et al. The proteome of primary prostate cancer. Eur Urol. 2016;69(5):942–52.PubMedCrossRef
292.
293.
Zhao X, Qin W, Jiang Y, Yang Z, Yuan B, Dai R, et al. ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. NPJ Precis Oncol. 2020;4:7.PubMedPubMedCentralCrossRef
294.
Yu DL, Li HW, Wang Y, Li CQ, You D, Jiang L, et al. Acyl-CoA dehydrogenase long chain expression is associated with esophageal squamous cell carcinoma progression and poor prognosis. Onco Targets Ther. 2018;11:7643–53.PubMedPubMedCentralCrossRef
295.
Zhang J, Ibrahim MM, Sun M, Tang J. Enoyl-coenzyme A hydratase in cancer. Clin Chim Acta. 2015;448:13–7.PubMedCrossRef
296.
Zhang YK, Qu YY, Lin Y, Wu XH, Chen HZ, Wang X, et al. Enoyl-CoA hydratase-1 regulates mTOR signaling and apoptosis by sensing nutrients. Nat Commun. 2017;8(1):464.PubMedPubMedCentralCrossRef
297.
Qu YY, Zhao R, Zhang HL, Zhou Q, Xu FJ, Zhang X, et al. Inactivation of the AMPK-GATA3-ECHS1 pathway induces fatty acid synthesis that promotes clear cell renal cell carcinoma growth. Cancer Res. 2020;80(2):319–33.PubMedCrossRef
298.
Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966–75.PubMedPubMedCentralCrossRef
299.
Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, et al. Lipid degradation promotes prostate cancer cell survival. Oncotarget. 2017;8(24):38264–75.PubMedPubMedCentralCrossRef
300.
Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM, et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife. 2020;9:e54166.PubMedPubMedCentralCrossRef
301.
Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun. 2020;11(1):2508.PubMedPubMedCentralCrossRef
302.
Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 2005;24(33):5173–90.PubMedPubMedCentralCrossRef
303.
Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, et al. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol. 2007;27(18):6361–71.PubMedPubMedCentralCrossRef
304.
Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, et al. Peroxisomes and cancer: the role of a metabolic specialist in a disease of aberrant metabolism. Biochim Biophys Acta Rev Cancer. 2018;1870(1):103–21.PubMedCrossRef
305.
Houten SM, Wanders RJA, Ranea-Robles P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165720.PubMedCrossRefPubMedCentral
306.
307.
Hlavac V, Soucek P. Role of family D ATP-binding cassette transporters (ABCD) in cancer. Biochem Soc Trans. 2015;43(5):937–42.PubMedCrossRef
308.
Hunt MC, Siponen MI, Alexson SE. The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism. Biochim Biophys Acta. 2012;1822(9):1397–410.PubMedCrossRef
309.
Bandu R, Mok HJ, Kim KP. Phospholipids as cancer biomarkers: mass spectrometry-based analysis. Mass Spectrom Rev. 2018;37(2):107–38.PubMedCrossRef
310.
Miryaghoubzadeh J, Darabi M, Madaen K, Shaaker M, Mehdizadeh A, Hajihosseini R. Tissue fatty acid composition in human urothelial carcinoma. Br J Biomed Sci. 2013;70(1):1–5.PubMedCrossRef
311.
Dierge E, Feron O. Dealing with saturated and unsaturated fatty acid metabolism for anticancer therapy. Curr Opin Clin Nutr Metab Care. 2019;22(6):427–33.PubMedCrossRef
312.
Bushell SR, Pike ACW, Falzone ME, Rorsman NJG, Ta CM, Corey RA, et al. The structural basis of lipid scrambling and inactivation in the endoplasmic reticulum scramblase TMEM16K. Nat Commun. 2019;10(1):3956.PubMedPubMedCentralCrossRef
313.
Lorent JH, Levental KR, Ganesan L, Rivera-Longsworth G, Sezgin E, Doktorova M, et al. Plasma membranes are asymmetric in lipid unsaturation, packing and protein shape. Nat Chem Biol. 2020;16(6):644–52.PubMedPubMedCentralCrossRef
314.
Kusumi A, Fujiwara TK, Tsunoyama TA, Kasai RS, Liu AA, Hirosawa KM, et al. Defining raft domains in the plasma membrane. Traffic. 2020;21(1):106–37.PubMedCrossRef
315.
316.
Wang B, Tontonoz P. Phospholipid remodeling in physiology and disease. Annu Rev Physiol. 2019;81:165–88.PubMedCrossRef
317.
Kim JY, Kim G, Lim SC, Choi HS. LPIN1 promotes epithelial cell transformation and mammary tumourigenesis via enhancing insulin receptor substrate 1 stability. Carcinogenesis. 2016;37(12):1199–209.PubMed
318.
Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, et al. G0S2 Suppresses oncogenic transformation by repressing a MYC-regulated transcriptional program. Cancer Res. 2016;76(5):1204–13.PubMedPubMedCentralCrossRef
319.
Wendel AA, Lewin TM, Coleman RA. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta. 2009;1791(6):501–6.PubMedCrossRef
320.
321.
Zaidi N, Royaux I, Swinnen JV, Smans K. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms. Mol Cancer Ther. 2012;11(9):1925–35.PubMedCrossRef
322.
Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013;10(8):483–7.PubMedCrossRef
323.
324.
325.
Else PL. The highly unnatural fatty acid profile of cells in culture. Prog Lipid Res. 2020;77:101017.PubMedCrossRef
326.
Mozolewska P, Duzowska K, Pakiet A, Mika A, SledziNski T. Inhibitors of fatty acid synthesis and oxidation as potential anticancer agents in colorectal cancer treatment. Anticancer Res. 2020;40(9):4843–56.PubMedCrossRef
327.
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4–22.PubMedCrossRef
Metadata
Title
The diversity and breadth of cancer cell fatty acid metabolism
Authors
Shilpa R. Nagarajan
Lisa M. Butler
Andrew J. Hoy
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer & Metabolism / Issue 1/2021
Electronic ISSN: 2049-3002
DOI
https://doi.org/10.1186/s40170-020-00237-2

Other articles of this Issue 1/2021

Cancer & Metabolism 1/2021 Go to the issue

Research

Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness

Research

PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner

Research

Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma

Research

Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma

Research

Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

Research

Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits